Daniel C. Adelman
2018 - Aimmune Therapeutics
In 2018, Daniel C. Adelman earned a total compensation of $2.1M as Chief Medical Officer at Aimmune Therapeutics, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $182,600 |
|---|---|
| Option Awards | $1,200,251 |
| Salary | $427,333 |
| Stock Awards | $319,406 |
| Other | $2,000 |
| Total | $2,131,590 |
Adelman received $1.2M in option awards, accounting for 56% of the total pay in 2018.
Adelman also received $182.6K in non-equity incentive plan, $427.3K in salary, $319.4K in stock awards and $2K in other compensation.
Rankings
In 2018, Daniel C. Adelman's compensation ranked 5,384th out of 14,244 executives tracked by ExecPay. In other words, Adelman earned more than 62.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,384 out of 14,244 | 62nd |
Division Manufacturing | 2,031 out of 5,765 | 65th |
Major group Chemicals And Allied Products | 741 out of 2,128 | 65th |
Industry group Drugs | 621 out of 1,817 | 66th |
Industry Pharmaceutical Preparations | 478 out of 1,391 | 66th |
Source: SEC filing on April 10, 2019.
Adelman's colleagues
We found five more compensation records of executives who worked with Daniel C. Adelman at Aimmune Therapeutics in 2018.
2018
Jayson Dallas
Aimmune Therapeutics
Chief Executive Officer
2018
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2018
Eric Bjerkholt
Aimmune Therapeutics
Chief Financial Officer
2018
Stephen Dilly
Aimmune Therapeutics
Chief Executive Officer
2018
Susan Barrowcliffe
Aimmune Therapeutics